NCT00036296

Effects of Talampanel on Patients With Advanced Parkinson's Disease

Effects of Talampanel on Patients With Advanced Parkinson's Disease Who Have Been on Sinemet for More Than 5 Years and Have Dyskinesia (Abnormal Involuntary Movements)

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 22 (actual)
• Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. · Industry
• Sex: All
• Age: 40 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this research study is to test the safety and effectiveness of the study drug, Talampanel, when used to treat patients with involuntary movements known as dyskinesias, as a result of treatment to Parkinson's disease. It is not clear why people with Parkinson's disease develop involuntary movements (dyskinesias) but studies show that blocking receptors in the brain for a chemical called glutamate decreases these movements. Talampanel is a drug which blocks these receptors.

Conditions

• Dyskinesias
• Parkinson Disease
• Movement Disorders

Interventions

Type	Name	Description
DRUG	talampanel	75mg per day divided into 3 doses for 22 days

Timeline

• Start date: 2006-12-01
• Primary completion: 2007-02-01
• Completion: 2007-02-01
• First posted: 2002-05-09
• Last updated: 2011-04-13